1
0
0
News
Milliarden-Boost für Tubulis durch Bristol Myers SquibbGoingPublic.de
www.goingpublic.de
— “ Das Tubulis-Management-Team v.l.n.r.: CMO Dr. Günter Fingerle-Rowson, MD, CSO Dr. Jonas Helma-Smets, CEO Dr. Dominik Schumacher, CBO Dr — “ Das Tubulis-Management-Team v.l.n.r.: CMO Dr. Günter Fingerle-Rowson, MD, CSO Dr. Jonas Helma-Smets, CEO Dr. Dominik Schumacher, CBO Dr ...
Tubulis appoints Günter Fingerle-Rowson as ...Tubulis
tubulis.com
MUNICH, GERMANY, April 20, 2021– Tubulis,today announced the appointment of Günter Fingerle-Rowson, MD, PhD, as Chief Medical Officer to complement the ...
Tubulis: Entwicklung innovativer KrebstherapienGoingPublic.de
www.goingpublic.de
— Das Tubulis-Management-Team v.l.n.r.: CMO Dr. Günter Fingerle-Rowson, MD, CSO Dr. Jonas Helma-Smets, CEO Dr. Dominik — Das Tubulis-Management-Team v.l.n.r.: CMO Dr. Günter Fingerle-Rowson, MD, CSO Dr. Jonas Helma-Smets, CEO Dr. Dominik ...
128 million euro round for TubulisStartbase
www.startbase.com
— Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher (CEO, Mitglied des Aufsichtsrates), Dr. Ingo Lehrke — Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher (CEO, Mitglied des Aufsichtsrates), Dr. Ingo Lehrke ...
Netzwerk-Profile
LinkedIn: Günter Fingerle-Rowson – Chief Medical OfficerLinkedIn
Günter Fingerle-Rowson · Chief Medical Officer at Tubulis GmbH · Melden · Melden · Info · Aktivitäten · Berufserfahrung · Ausbildung · Weitere Aktivitäten von Günter ...
LinkedIn: Günter Fingerle-Rowson - technology #adc #cd30 - LinkedInmy.linkedin.com › posts › günter-fingerle-rowson
Paparan Günter Fingerle-Rowson. Lihat profil Günter Fingerle-Rowson · Günter Fingerle-Rowson. Chief Medical Officer at Tubulis GmbH.
LinkedIn: Günter Fingerle-Rowson's Post - technology #adc #cd30linkedin.com
Günter Fingerle-Rowson's Post. View profile for Günter Fingerle-Rowson · Günter Fingerle-Rowson. Chief Medical Officer at Tubulis GmbH.
Browse by People - ePrints Soton - University of SouthamptonePrints Soton
eprints.soton.ac.uk
... Günter Fingerle-Rowson, Kaspar Rufibach, Tom Moore, Michael Herold and Wolfgang Hiddemann. Type: Article | | Item not available on this server. This Günter Fingerle-Rowson, Kaspar Rufibach, Tom Moore, Michael Herold and Wolfgang Hiddemann. Type: Article | | Item not available on this server. This ...
Interessen
Original Article Obinutuzumab for the First-Line Treatment ...The New England Journal of Medicine
www.nejm.org
B., Marek Trněný, M.D., Michael Wenger, M.D., Günter Fingerle-Rowson, M.D., Ph.D., Kaspar Rufibach, Ph.D., Tom Moore, M.B., Ch.B., Michael Herold, M.D., and ... B., Marek Trněný, M.D., Michael Wenger, M.D., Günter Fingerle-Rowson, M.D., Ph.D., Kaspar Rufibach, Ph.D., Tom Moore, M.B., Ch.B., Michael Herold, M.D., and ...
Obinutuzumab plus bendamustine versus ...The Lancet
www.thelancet.com
... Günter Fingerle-Rowson, MD, Prof Bruce D Cheson, MD. The Lancet Oncology. Volume 17 Issue 8 Pages (August 2016). DOI: S (16) Günter Fingerle-Rowson, MD, Prof Bruce D Cheson, MD. The Lancet Oncology. Volume 17 Issue 8 Pages (August 2016). DOI: S (16)
Obinutuzumab plus bendamustine versus ...EM consulte
www.em-consulte.com
... Günter Fingerle-Rowson, MD, Bruce D Cheson, ProfMD. a British Columbia Cancer Agency, Vancouver, BC, Canada. b University of British Columbia, Vancouver Günter Fingerle-Rowson, MD, Bruce D Cheson, ProfMD. a British Columbia Cancer Agency, Vancouver, BC, Canada. b University of British Columbia, Vancouver ...
a multicentre, prospective, single-arm, phase 2 studyThe Lancet
www.thelancet.com
... Günter Fingerle-Rowson, MD, Kami Maddocks, MD. The Lancet Oncology. Volume 21 Issue 7 Pages (July 2020). DOI: S (20) Copyright Günter Fingerle-Rowson, MD, Kami Maddocks, MD. The Lancet Oncology. Volume 21 Issue 7 Pages (July 2020). DOI: S (20) Copyright ...
Business-Profile
Xing: Günter Fingerle-Rowson - Medical Director
WebGünter Fingerle-Rowson Basis Ganzes Profil ansehen Angestellt, Medical Director, Hoffmann LaRoche Basel, …
Günter FINGERLE-ROWSON | Doctor of MedicineResearchGate
www.researchgate.net
Günter FINGERLE-ROWSON | Cited by | | Read 161 publications | Contact Günter FINGERLE-ROWSON. Günter FINGERLE-ROWSON | Cited by | | Read 161 publications | Contact Günter FINGERLE-ROWSON.
Günter KRAUSE | Group Leader | Dr. rer. nat.ResearchGate
www.researchgate.net
Günter Fingerle-Rowson. Unlabelled: Survival of chronic lymphocytic leukemia (CLL) cells depends on stimuli provided by a suitable ... Günter Fingerle-Rowson. Unlabelled: Survival of chronic lymphocytic leukemia (CLL) cells depends on stimuli provided by a suitable ...
Private Homepages
Günter Fingerle-Rowson's Email & Phone - MorphoSys AGContactOut
contactout.com
View Günter Fingerle-Rowson's business profile as Vice President, Business Team Head MOR208 at MorphoSys AG. Get Günter Fingerle-Rowson's email, phone, ...
Bücher
Macrophage Migration Inhibitory Factor Coordinates DNA ...Taylor & Francis Online
www.tandfonline.com
von A Nemajerova · · Zitiert von: 50 — ,. Ute M. Moll. ,. Oleksi Petrenko. &. Günter Fingerle-Rowson. Pages | Published online: 01 May Cite this article · https://doi.org cc. von A Nemajerova · · Zitiert von: 50 — ,. Ute M. Moll. ,. Oleksi Petrenko. &. Günter Fingerle-Rowson. Pages | Published online: 01 May Cite this article · https://doi.org cc.
Publications matching author Günter Fingerle-RowsonMinso Solutions AB
ci.minso.se
... Günter Fingerle-Rowson 1, Matthias Ritgen 1, Michael Kneba 1, Hartmut Döhner 1, Stephan Stilgenbauer 1, Wolfram Klapper 1, Clemens-Martin Wendtner Günter Fingerle-Rowson 1, Matthias Ritgen 1, Michael Kneba 1, Hartmut Döhner 1, Stephan Stilgenbauer 1, Wolfram Klapper 1, Clemens-Martin Wendtner
Successful Drug Discovery, Volume 3google.lv
books.google.lv
... Günter Fingerle-Rowson, and Pablo Umaña Introduction 245 Preclinical Experience with Obinutuzumab 246 Characteristics and Mechanisms of Action of Type I and ...
Combination therapy with the type II anti-CD20 antibody ...Taylor & Francis Online
www.tandfonline.com
von C Klein · · Zitiert von: 8 — Günter Fingerle-RowsonPharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information. Pages von C Klein · · Zitiert von: 8 — Günter Fingerle-RowsonPharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information. Pages
Dokumente zum Namen
American Journal of Hematology | Blood Research JournalWiley Online Library
onlinelibrary.wiley.com
von O Al‐Sawaf · · Zitiert von: 7 — ... Günter Fingerle-Rowson,. Günter Fingerle-Rowson. F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers by this author · Stephan ... von O Al‐Sawaf · · Zitiert von: 7 — ... Günter Fingerle-Rowson,. Günter Fingerle-Rowson. F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers by this author · Stephan ...
Discovery and Development of Obinutuzumab (GAZYVA ...Wiley Online Library
onlinelibrary.wiley.com
von C Klein · · Zitiert von: 1 — Günter Fingerle-Rowson,. Günter Fingerle-Rowson. Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers ... von C Klein · · Zitiert von: 1 — Günter Fingerle-Rowson,. Günter Fingerle-Rowson. Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers ...
Delayed development of chronic lymphocytic leukemia in the ...ashpublications.org
ashpublications.org
von N Reinart · · Zitiert von: 110 — Günter Fingerle-Rowson. Günter Fingerle-Rowson. 1Department I of Internal Medicine, University Hospital Cologne, and Center for Integrated Oncology Köln-Bonn ... von N Reinart · · Zitiert von: 110 — Günter Fingerle-Rowson. Günter Fingerle-Rowson. 1Department I of Internal Medicine, University Hospital Cologne, and Center for Integrated Oncology Köln-Bonn ...
Obinutuzumab or Rituximab Plus Cyclophosphamide, ...Swiss Open Access Repository
sonar.ch
von U Vitolo · · Zitiert von: 420 — Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger ... von U Vitolo · · Zitiert von: 420 — Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger ...
Wissenschaftliche Veröffentlichungen
Privatdozent Dr. Günter Fingerle-Rowson - GEPRIS - DFGDFG - GEPRIS
gepris.dfg.de
Privatdozent Dr. Günter Fingerle-Rowson, Klinik für Innere Medizin IKöln. Privatdozent Dr. Günter Fingerle-Rowson, Klinik für Innere Medizin IKöln.
MIF coordinates the cell cycle with DNA damage checkpoints ...BioMed Central
celldiv.biomedcentral.com
von G Fingerle-Rowson · · Zitiert von: 48 — MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Günter Fingerle-Rowson &; Oleksi Petrenko. Cell ... von G Fingerle-Rowson · · Zitiert von: 48 — MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Günter Fingerle-Rowson &; Oleksi Petrenko. Cell ...
Treatment of Indolent Lymphoma in GermanyScienceDirect.com
www.sciencedirect.com
von C Schmidt · · Zitiert von: 11 — , Lenka Kellermann 7 , Wolfgang Hiddemann 1 , Guenter Fingerle-Rowson 8 , Martin Dreyling 1. Show more. Add to Mendeley. Share. Cite. https://doi.org von C Schmidt · · Zitiert von: 11 — , Lenka Kellermann 7 , Wolfgang Hiddemann 1 , Guenter Fingerle-Rowson 8 , Martin Dreyling 1. Show more. Add to Mendeley. Share. Cite. https://doi.org
DFG - GEPRIS - Privatdozent Dr. Günter Fingerle-Rowson
gepris.dfg.de
WebPrivatdozent Dr. Günter Fingerle-Rowson, Klinik für Innere Medizin I: Onkologie, Hämatologie, Klinische Infektiologie, Klinische Immunologie, Hämostaseologie, …
Veröffentlichungen allgemein
A Review of Obinutuzumab (GA101), a Novel Type II Anti- ...Springer
link.springer.com
von K Tobinai · · Zitiert von: 168 — Günter Fingerle-Rowson is an employee at F. Hoffmann-La Roche Ltd. and owns stock in F. Hoffmann-La Roche Ltd. Compliance with Ethics ... von K Tobinai · · Zitiert von: 168 — Günter Fingerle-Rowson is an employee at F. Hoffmann-La Roche Ltd. and owns stock in F. Hoffmann-La Roche Ltd. Compliance with Ethics ...
Expansion of CD14+CD16+Monocytes in Critically Ill ...Springer
link.springer.com
von G Fingerle-Rowson · · Zitiert von: 109 — Authors and Affiliations. Department of Internal Medicine I, Klinikum Grosshadern, University of Muenchen, Muenchen, FRG. Günter Fingerle-Rowson & Jens Auers. von G Fingerle-Rowson · · Zitiert von: 109 — Authors and Affiliations. Department of Internal Medicine I, Klinikum Grosshadern, University of Muenchen, Muenchen, FRG. Günter Fingerle-Rowson & Jens Auers.
Table of Contents | International Journal of Cell Biologywww.hindawi.com › journals › ijcb › contents › year
www.hindawi.com
Nic E. Savaskan | Günter Fingerle-Rowson | ... | Ilker Y. Eyüpoglu. 03 Sep 2012; PDFDownload PDF · CitationDownload citation.
Günter Fingerle-Rowson Selected ResearchCureHunter
www.curehunter.com
Günter Fingerle-Rowson Selected Research. Günter Fingerle-Rowson Research Topics. Disease. 4, Neoplasms (Cancer) , Rheumatoid Arthritis
Video & Audio
Tubulis schließt strategische Partnerschaft mit BMSInnovations- und Gründerzentrum Biotechnologie IZB
www.izb-online.de
— Günter Fingerle-Rowson, MD, CMO; Dr. Jonas Helma-Smets, CSO; Dr. Dominik Schumacher, CEO; Dr. Ingo Lehrke, CBO; Dr. Björn Hock, CDO — Günter Fingerle-Rowson, MD, CMO; Dr. Jonas Helma-Smets, CSO; Dr. Dominik Schumacher, CEO; Dr. Ingo Lehrke, CBO; Dr. Björn Hock, CDO ...
m 4 Award Gewinner Tubulis auf Erfolgsspur: 128 Mio. Euro ...bio-m.org
www.bio-m.org
— Das Managementteam der Tubulis GmbH (v.l.n.r.): Dr. Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher — Das Managementteam der Tubulis GmbH (v.l.n.r.): Dr. Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher ...
Artikel & Meinungen
128 Mio. EUR Runde für Münchner Biotech-Start-up TubulisVC Magazin
www.vc-magazin.de
— Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher (CEO, Mitglied des Aufsichtsrates), Dr. Ingo Lehrke (CBO) — Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher (CEO, Mitglied des Aufsichtsrates), Dr. Ingo Lehrke (CBO) ...
MRD response in relapsed/refractory FL after ...Nature Journal
www.nature.com
von C Pott · · Zitiert von: 19 — Nathalie Spielewoy, Guenter Fingerle-Rowson, Kirsten Mundt & Elisabeth Wassner-Fritsch. Roche, Welwyn Garden City, UK. Chris Harbron.
Sonstiges
Guenter Fingerle-RowsonLinkos.cz
www.linkos.cz
Guenter Fingerle-Rowson. Pharma Development, F. Hoffmann-La Roche Ltd. ( Basel, Switzerland). Odborné práce publikované na Linkos.cz. Přehled odborných textů ... Guenter Fingerle-Rowson. Pharma Development, F. Hoffmann-La Roche Ltd. ( Basel, Switzerland). Odborné práce publikované na Linkos.cz. Přehled odborných textů ...
Günter Fingerle-Rowson (fingerlerowson) - ProfilePinterest - Deutschland
www.pinterest.de
See what Günter Fingerle-Rowson (fingerlerowson) has discovered on Pinterest, the world's biggest collection of ideas. See what Günter Fingerle-Rowson (fingerlerowson) has discovered on Pinterest, the world's biggest collection of ideas.
Günter Fingerle-Rowson - CMO at TubulisThe Org
theorg.com
Günter Fingerle-Rowson is the current CMO at Tubulis. Günter has also previously worked as an Associate Group Medical Director, Global Development Team ... Günter Fingerle-Rowson is the current CMO at Tubulis. Günter has also previously worked as an Associate Group Medical Director, Global Development Team ...
"MRD response in relapsed/refractory FL after ...Digital Commons@Becker
digitalcommons.wustl.edu
von C Pott · · Zitiert von: 29 — ... Guenter Fingerle-Rowson, F. Hoffmann-La Roche Ltd · Chris Harbron, Roche · Kirsten Mundt, F. Hoffmann-La Roche Ltd · Elisabeth Wassner-Fritsch, ... von C Pott · · Zitiert von: 29 — ... Guenter Fingerle-Rowson, F. Hoffmann-La Roche Ltd · Chris Harbron, Roche · Kirsten Mundt, F. Hoffmann-La Roche Ltd · Elisabeth Wassner-Fritsch, ...
A model for predicting effect of treatment on progression-free ...ashpublications.org
ashpublications.org
Günter Fingerle-Rowson,. Günter Fingerle-Rowson. 2F. Hoffmann-La Roche Ltd, Basel, Switzerland;. Search for other works by this author on: This Site · PubMed. Günter Fingerle-Rowson,. Günter Fingerle-Rowson. 2F. Hoffmann-La Roche Ltd, Basel, Switzerland;. Search for other works by this author on: This Site · PubMed.
BioTech-Innovation im Kampf gegen Krebs: 128 Millionen ...Gründerland Bayern
www.gruenderland.bayern
... Günter Fingerle-Rowson, Dr. Jonas Helma-Smets, Dr. Dominik Schumacher, Dr. Ingo Lehrke und Dr. Björn Hock. © Tubulis März 24. BioTech-Innovation im Günter Fingerle-Rowson, Dr. Jonas Helma-Smets, Dr. Dominik Schumacher, Dr. Ingo Lehrke und Dr. Björn Hock. © Tubulis März 24. BioTech-Innovation im ...
HarvardHaematologica
haematologica.org
Paulson, Eugene Kim, Umberto Vitolo, Alice Di Rocco, Günter Fingerle-Rowson, Tina Nielsen, Georg Lenz and Mikkel Z. Oestergaard (2019) “Prognostic impact of ... Paulson, Eugene Kim, Umberto Vitolo, Alice Di Rocco, Günter Fingerle-Rowson, Tina Nielsen, Georg Lenz and Mikkel Z. Oestergaard (2019) “Prognostic impact of ...
Immunochemotherapy With Obinutuzumab or Rituximab for ...Research Explorer The University of Manchester
research.manchester.ac.uk
von W Hiddemann — ... Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus. Division of Cancer Sciences (L5). Research output: Contribution to journal › Article ... von W Hiddemann — ... Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus. Division of Cancer Sciences (L5). Research output: Contribution to journal › Article ...
Influence of Chemotherapy on Efficacy and SafetyASCO Publications
ascopubs.org
Günter Fingerle-Rowson. Employment: Roche. Stock or Other Ownership: Roche. Marcel Wolbers. Employment: Roche. Consulting or Advisory Role: Roche. Tina Nielsen. Günter Fingerle-Rowson. Employment: Roche. Stock or Other Ownership: Roche. Marcel Wolbers. Employment: Roche. Consulting or Advisory Role: Roche. Tina Nielsen.
Influence of Chemotherapy on Efficacy and SafetyResearch Explorer The University of Manchester
research.manchester.ac.uk
von W Hiddemann · · Zitiert von: 220 — ... Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus. Division of Cancer Sciences (L5). Research output: Contribution to journal › Article ... von W Hiddemann · · Zitiert von: 220 — ... Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus. Division of Cancer Sciences (L5). Research output: Contribution to journal › Article ...
Journal of Hematology & Multiple Myeloma | HomeRemedy Publications
www.remedypublications.com
John Wagstaff · Sherry Baldwin · Leonidas C Platanias · Günter Fingerle-Rowson · Andrei Braester · A Bouazzaoui · AppalaNaidu Sasapu · Helen S L Chan. John Wagstaff · Sherry Baldwin · Leonidas C Platanias · Günter Fingerle-Rowson · Andrei Braester · A Bouazzaoui · AppalaNaidu Sasapu · Helen S L Chan.
MIF but not MIF-2 recruits inflammatory macrophages in an ...JCI.org
www.jci.org
... Tilstam, … , Günter Fingerle-Rowson, Richard Bucala. Pathricia Veronica Tilstam, … , Günter Fingerle-Rowson, Richard Bucala. Published December 1, Tilstam, … , Günter Fingerle-Rowson, Richard Bucala. Pathricia Veronica Tilstam, … , Günter Fingerle-Rowson, Richard Bucala. Published December 1, 2021
MIF coordinates the cell cycle with DNA damage ...National Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von G Fingerle-Rowson · · Zitiert von: 48 — doi: Authors. Günter Fingerle-Rowson , Oleksi Petrenko. Affiliation. 1 University Hospital Cologne, Clinic I of Internal Medicine ... von G Fingerle-Rowson · · Zitiert von: 48 — doi: Authors. Günter Fingerle-Rowson , Oleksi Petrenko. Affiliation. 1 University Hospital Cologne, Clinic I of Internal Medicine ...
MRD response in relapsed/refractory FL after ...Washington University in St. Louis
profiles.wustl.edu
... Guenter Fingerle-Rowson, Chris Harbron, Kirsten Mundt, Elisabeth Wassner-Fritsch, Bruce D. Cheson. Section of Medical Oncology · Siteman Cancer Center. Research Guenter Fingerle-Rowson, Chris Harbron, Kirsten Mundt, Elisabeth Wassner-Fritsch, Bruce D. Cheson. Section of Medical Oncology · Siteman Cancer Center. Research ...
Macrophage Migration Inhibitory Factor Enzymatic Activity, ...ATS Journals
www.atsjournals.org
von H Adamali · · Zitiert von: 64 — , Günter Fingerle-Rowson. x. Günter Fingerle-Rowson. Search for articles by this author. , Richard J. Bucala. x. Richard J. Bucala. Search for ... von H Adamali · · Zitiert von: 64 — , Günter Fingerle-Rowson. x. Günter Fingerle-Rowson. Search for articles by this author. , Richard J. Bucala. x. Richard J. Bucala. Search for ...
Macrophage migration inhibitory factor protects from ...National Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von T Brocks · · Zitiert von: 28 — ... Guenter Fingerle-Rowson. Affiliations. 1 Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany. 2 Center for Integrated ... von T Brocks · · Zitiert von: 28 — ... Guenter Fingerle-Rowson. Affiliations. 1 Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany. 2 Center for Integrated ...
Obinutuzumab plus bendamustine versus ...Elsevier
mdanderson.elsevierpure.com
Lugtenburg, Natalie Dimier, Elisabeth Wassner-Fritsch, Günter Fingerle-Rowson, Bruce D. Cheson. Lymphoma-Myeloma. Research output: Contribution to journal ... Lugtenburg, Natalie Dimier, Elisabeth Wassner-Fritsch, Günter Fingerle-Rowson, Bruce D. Cheson. Lymphoma-Myeloma. Research output: Contribution to journal ...
Obinutuzumab plus bendamustine versus ...Masarykova univerzita
www.muni.cz
von LH Sehn · · Zitiert von: 371 — ... Günter FINGERLE-ROWSON and Bruce D CHESON. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non ... von LH Sehn · · Zitiert von: 371 — ... Günter FINGERLE-ROWSON and Bruce D CHESON. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non ...
Overall Survival Benefit in Patients With Rituximab- ...ASCO Publications
ascopubs.org
Lugtenburg, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; and Günter Fingerle-Rowson, Federico Mattiello, and Andrea Knapp, F. Hoffmann-La Roche, ... Lugtenburg, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; and Günter Fingerle-Rowson, Federico Mattiello, and Andrea Knapp, F. Hoffmann-La Roche, ...
Randomized Phase II Trial Comparing Obinutuzumab ...Europe PMC
europepmc.org
von LH Sehn · · Zitiert von: 179 — ... Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research ... von LH Sehn · · Zitiert von: 179 — ... Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research ...
Verwandte Suchanfragen zu Günter Fingerle-Rowson
| Marcel Wolbers Michael Kneba Georg Lenz | Kaspar Rufibach Andreas Meinhardt Clemens-Martin Wendtner | Jörg Klug Dominik Schumacher Kirsten Fischer |
Personen Vorname "Günter" (29119) Name |
sortiert nach Relevanz / Datum